DK1146862T3 - Farmaceutiske sammensætninger - Google Patents

Farmaceutiske sammensætninger

Info

Publication number
DK1146862T3
DK1146862T3 DK99900623T DK99900623T DK1146862T3 DK 1146862 T3 DK1146862 T3 DK 1146862T3 DK 99900623 T DK99900623 T DK 99900623T DK 99900623 T DK99900623 T DK 99900623T DK 1146862 T3 DK1146862 T3 DK 1146862T3
Authority
DK
Denmark
Prior art keywords
gastric
particles
polymer
active ingredient
intestinal juices
Prior art date
Application number
DK99900623T
Other languages
English (en)
Inventor
Gerald Huber
Peter Gruber
Original Assignee
Disphar Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disphar Int Bv filed Critical Disphar Int Bv
Application granted granted Critical
Publication of DK1146862T3 publication Critical patent/DK1146862T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99900623T 1999-01-29 1999-01-29 Farmaceutiske sammensætninger DK1146862T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1999/000180 WO2000044353A1 (de) 1999-01-29 1999-01-29 Pharmazeutische zusammensetzungen

Publications (1)

Publication Number Publication Date
DK1146862T3 true DK1146862T3 (da) 2003-07-21

Family

ID=11004817

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99900623T DK1146862T3 (da) 1999-01-29 1999-01-29 Farmaceutiske sammensætninger

Country Status (15)

Country Link
US (1) US6962717B1 (da)
EP (1) EP1146862B1 (da)
JP (1) JP2002535353A (da)
AT (1) ATE238040T1 (da)
AU (1) AU764469B2 (da)
BR (1) BR9916972B1 (da)
CA (1) CA2360655C (da)
DE (1) DE59905248D1 (da)
DK (1) DK1146862T3 (da)
ES (1) ES2197600T3 (da)
MX (1) MXPA01007463A (da)
NO (1) NO329231B1 (da)
NZ (1) NZ513037A (da)
PT (1) PT1146862E (da)
WO (1) WO2000044353A1 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
PT1190712E (pt) * 2000-09-22 2005-01-31 Smb Technology Composicao de esferas de tramadol para administracao oral uma vez por dia
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
DE60124895D1 (de) * 2001-07-26 2007-01-11 Ethypharm Sa Umgehüllte Allylamine oder Benzylamine enthaltende Granulate, Verfahren zur Herstellung und in der Mundhöhle dispergierbare Tabletten enthaltend die umgehüllten Granulate
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2011205217B2 (en) * 2001-08-06 2013-06-13 Euro-Celtique S.A. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
MXPA04006780A (es) * 2002-01-11 2005-06-08 Athpharma Ltd Formulaciones farmaceuticas de pravastatina y metodos para usarlas.
US20040028729A1 (en) * 2002-04-29 2004-02-12 Shojaei Amir H. Pharmaceutical formulations with improved bioavailability
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
WO2004093883A2 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
CN1835765A (zh) * 2003-08-13 2006-09-20 霍华德·J·史密斯及同仁控股有限公司 治疗病毒感染的方法
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
EP1689373B1 (en) * 2003-10-10 2019-04-03 Ethypharm Sustained-release microgranules containing ginkgo biloba extract and the process for manufacturing these
DE602004030931D1 (da) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
EP1547601A1 (en) * 2003-12-23 2005-06-29 Ferring B.V. Coating method
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US7662802B2 (en) * 2004-09-17 2010-02-16 Gluconova, LLC Halide-free glucosamine-acidic drug complexes
RU2403033C2 (ru) 2005-03-22 2010-11-10 Лозан Фарма Гмбх Солюбилизированный ибупрофен
GR1006875B (el) * 2005-06-30 2010-07-12 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
US11311490B2 (en) 2005-08-10 2022-04-26 Add Advanced Drug Delivery Technologies Ltd. Oral preparation with controlled release
SI1931346T1 (sl) 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
ES2620293T3 (es) 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2008023027A2 (en) * 2006-08-24 2008-02-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing pramipexole dihydrochloride tablets with high storage stability
EP2063872B2 (en) 2006-08-30 2019-12-04 Jagotec AG Controlled release oral dosage formulations comprising a core and one or more barrier layers
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2009065142A2 (en) 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
AU2009265099A1 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising Quetiapine
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CN107260756A (zh) 2009-10-14 2017-10-20 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
EP2340812A1 (en) * 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
US20140112983A1 (en) * 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
WO2013090893A1 (en) * 2011-12-16 2013-06-20 Celanese Eva Performance Polymers, Inc. Gastroretentive controlled release vehicles that include ethylene copolymers, ethyl celluloses, and/or thermpoplastic polyurethanes
JP2015508789A (ja) * 2012-03-02 2015-03-23 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 医薬製剤
US9730885B2 (en) 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CN105358160A (zh) 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途
US8652527B1 (en) * 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN104922078B (zh) * 2015-06-23 2018-10-23 上海市计划生育科学研究所 非诺贝特迟释微丸、制备方法及应用
BE1024339B1 (fr) * 2016-07-01 2018-01-29 Be Pharbel Mfg Sa Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide
CN108348475B (zh) 2015-07-17 2022-01-04 比利时法贝尔制造股份有限公司 处于液体剂型的多层药学活性化合物释放微粒
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
EP3117824A1 (en) * 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
ITUA20162293A1 (it) 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2017295866A1 (en) 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
WO2018129061A1 (en) * 2017-01-05 2018-07-12 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
DK58983D0 (da) 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
SE457505B (sv) 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DK62184D0 (da) 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
DE3678641D1 (de) 1985-08-16 1991-05-16 Procter & Gamble Partikel mit konstanter wirkstofffreisetzung.
SE455836B (sv) 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
AU591248B2 (en) 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
SE9002017D0 (sv) 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
JP3286315B2 (ja) 1990-06-20 2002-05-27 アドバンスト ポリマー システムズ，インコーポレイティド 可溶性活性物質の調節された放出のための組成物及び方法
SE9002339L (sv) 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
GB9025372D0 (en) 1990-11-22 1991-01-09 Nat Res Dev Pharmaceutical dosage forms
GEP19971086B (en) 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
WO1992016214A1 (en) 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
JPH07223970A (ja) 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
JP2917799B2 (ja) 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
UA67721C2 (en) 1995-12-21 2004-07-15 Ferring Farma Lab Modified release pharmaceutical composition and method for treatment of inflammatory bowel diseases
DK0876142T3 (da) * 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
NZ335737A (en) 1996-11-12 2000-09-29 Pharmacia & Upjohn Ab Compact member comprising a plurality of porous cellulose matrices (PCMs)

Also Published As

Publication number Publication date
CA2360655C (en) 2007-03-20
PT1146862E (pt) 2003-09-30
US6962717B1 (en) 2005-11-08
NZ513037A (en) 2003-05-30
WO2000044353A1 (de) 2000-08-03
BR9916972A (pt) 2001-11-06
MXPA01007463A (es) 2002-06-04
NO20013336D0 (no) 2001-07-05
ATE238040T1 (de) 2003-05-15
AU764469B2 (en) 2003-08-21
EP1146862B1 (de) 2003-04-23
CA2360655A1 (en) 2000-08-03
BR9916972B1 (pt) 2010-05-18
JP2002535353A (ja) 2002-10-22
AU1980899A (en) 2000-08-18
DE59905248D1 (de) 2003-05-28
ES2197600T3 (es) 2004-01-01
EP1146862A1 (de) 2001-10-24
NO20013336L (no) 2001-09-25
NO329231B1 (no) 2010-09-20

Similar Documents

Publication Publication Date Title
PT1146862E (pt) Composicoes farmaceuticas
EP2277510A3 (en) Controlled release preparation
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
EP0390541A3 (en) Paste-like base and preparation
EP1690530A3 (en) Sustained release pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
DK0868910T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater som bindemidler til fremstilling af faste farmaceutiske dispergeringsformer
IT1251153B (it) Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
EP2322146A3 (en) Microcapsule formulations comprising two pharmaceutically active ingredients
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
NZ709754A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2004060405A3 (en) Tissue reactive compounds and compositions and uses thereof
CA2409828A1 (en) Formulation based in heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
EP2308479A3 (en) Compounds and compositions for delivering active agents
ATE482689T1 (de) Blockcopolymer-mizellenzusammensetzung mit verbesserter arzneimittelbeladungskapazität und verzögerter freisetzung
EP2311871A3 (en) IL-1 antagonist stable liquid formulation
MX2025001734A (es) Formas farmacéuticas sólidas orales que contienen cannabinoides
DE59909717D1 (de) Verfahren zur Herstellung von festen Dosierungsformen
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
TW200420304A (en) Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction
TW200624464A (en) Amphiphilic block copolymer and pharmaceutical formulation comprising the same
AU9124401A (en) Stabilization of solid thyroid drug formulations
EA200601283A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая нерастворимый в кислотах полимер и биоадгезивный полимер
TW200621224A (en) Pharmaceutical composition
TW200621304A (en) Pharmaceutical composition